US 12,440,427 B2
Skin dough composition
Denis Simioni, Saint-Placide (CA)
Filed by Denis Simioni, Saint-Placide (CA)
Filed on Aug. 4, 2023, as Appl. No. 18/365,607.
Claims priority of provisional application 63/370,598, filed on Aug. 5, 2022.
Prior Publication US 2024/0041706 A1, Feb. 8, 2024
Int. Cl. A61K 8/02 (2006.01); A61K 8/23 (2006.01); A61K 8/34 (2006.01); A61K 8/36 (2006.01); A61K 8/73 (2006.01); A61Q 19/00 (2006.01); A61Q 19/08 (2006.01)
CPC A61K 8/0212 (2013.01) [A61K 8/23 (2013.01); A61K 8/345 (2013.01); A61K 8/361 (2013.01); A61K 8/732 (2013.01); A61K 8/737 (2013.01); A61Q 19/007 (2013.01); A61Q 19/08 (2013.01); A61K 2800/87 (2013.01); A61K 2800/884 (2013.01)] 15 Claims
 
1. A skin dough composition for occlusive therapy, the composition comprising:
about 1.0 wt. % to about 15 wt. % of an emulsifier;
about 20 wt. % to about 40 wt. % of glycerin, wherein glycerin is a humectant and moisturizer in the skin dough composition;
about 20 wt. % to about 40 wt. % of C6-C18 medium chain glycerides;
about 0.1 wt. % to about 5.0 wt. % of non-crosslinked hydroxypropyl guar; and
about 1.0 wt. % to about 40.0 wt. % of a C16-C18 fatty acid salt;
wherein:
the skin dough composition is malleable and moldable and generally retains its shape after molding such that when molded to fit onto skin the composition provides tight and uniform dermal adhesion and complete cutaneous contact in occlusive therapy; and
the skin dough composition does not dry out and remains malleable over a treatment period for the occlusive therapy.